74461-35-1 Usage
General Description
1-(1H-Benzoimidazol-2-yl)-ethylamine, also known as benzimidazole, is a chemical compound with the molecular formula C9H10N2. It consists of a benzene ring fused to an imidazole ring, and it is commonly used as an intermediate in the synthesis of pharmaceuticals and agricultural chemicals. Benzimidazole has been found to exhibit antifungal, antiviral, and anticancer properties. It is also used as a building block in the production of dyes and plastics. Additionally, benzimidazole derivatives have been studied for their potential use in the treatment of neurodegenerative diseases and as anti-inflammatory agents. Overall, benzimidazole is a versatile compound with a wide range of potential applications in various industries.
Check Digit Verification of cas no
The CAS Registry Mumber 74461-35-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,4,4,6 and 1 respectively; the second part has 2 digits, 3 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 74461-35:
(7*7)+(6*4)+(5*4)+(4*6)+(3*1)+(2*3)+(1*5)=131
131 % 10 = 1
So 74461-35-1 is a valid CAS Registry Number.
InChI:InChI=1/C9H11N3/c1-6(10)9-11-7-4-2-3-5-8(7)12-9/h2-6H,10H2,1H3,(H,11,12)/p+1/t6-/m1/s1
74461-35-1Relevant articles and documents
BENZIMIDAZOLE COMPOUNDS THAT ARE VITRONECTIN RECEPTOR ANTAGONISTS
-
Page/Page column 30-31, (2008/06/13)
The present invention provides compounds having formula (I) wherein n, p, q and r are each independently selected from 0 or 1; a, b, c, and d each independently represents a carbon or nitrogen atom, with the proviso that no more than two of a, b, c, and d are nitrogen atoms; Y and Y' each independently represents 1-4 optional substituents selected from alkyl, alkoxy, halo, -CF3, and -C(O)OH; R, R, R and R are H or specified substituents; R, R, R, R, R, R, R and R are independently selected from H or C1-C3 alkyl; or a biolabile ester thereof, or a pharmaceutically acceptable salt thereof. Also provided are methods of using these compounds for treating vitronectin-mediated disorders, e.g., cancer, retinopathy, artherosclerosis, vascular restenosis, and osteoporosis.
